Journal of Clinical Medicine Review COVID-19: The Potential Treatment of Pulmonary Fibrosis Associated with SARS-CoV-2 Infection Kacper Lechowicz 1 , Sylwester Dro˙zd˙zal 2, Filip Machaj 3, Jakub Rosik 3 , Bartosz Szostak 3, Małgorzata Zegan-Bara ´nska 1, Jowita Biernawska 4 , Wojciech Dabrowski 5 , Iwona Rotter 6 and Katarzyna Kotfis 1,* 1 Department of Anaesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University, 70-111 Szczecin, Poland;
[email protected] (K.L.);
[email protected] (M.Z.-B.) 2 Department of Pharmacokinetics and Monitored Therapy, Pomeranian Medical University, 70-111 Szczecin, Poland;
[email protected] 3 Department of Physiology, Pomeranian Medical University, 70-111 Szczecin, Poland;
[email protected] (F.M.);
[email protected] (J.R.);
[email protected] (B.S.) 4 Department of Anaesthesiology and Intensive Therapy, Pomeranian Medical University, 71-242 Szczecin, Poland;
[email protected] 5 Department of Anaesthesiology and Intensive Care, Medical University, 20-090 Lublin, Poland;
[email protected] 6 Department of Medical Rehabilitation and Clinical Physiotherapy, Pomeranian Medical University, 71-210 Szczecin, Poland;
[email protected] * Correspondence: katarzyna.kotfi
[email protected]; Tel.: +48-91-466-11-44 Received: 1 May 2020; Accepted: 17 June 2020; Published: 19 June 2020 Abstract: In December 2019, a novel coronavirus, SARS-CoV-2, appeared, causing a wide range of symptoms, mainly respiratory infection. In March 2020, the World Health Organization (WHO) declared Coronavirus Disease 2019 (COVID-19) a pandemic, therefore the efforts of scientists around the world are focused on finding the right treatment and vaccine for the novel disease.